Page 6 - Glenmark Pharmaceuticals

Glenmark Pharmaceuticals net profit up 30% at Rs 248.17 cr in Dec qtr

Glenmark on Friday reported a 30.04 percent rise in its consolidated net profit to Rs 248.17 crore for the quarter ended December 2020

Sensex ends volatile trade 12 pts up; RIL jumps 6% this week, ITC down 7%

On the sectoral front, the Nifty Metal index skid 1.7 per cent, followed by the Nifty FMCG index declined 1.5 per cent

Glenmark Pharma gets USFDA approval for nervous system stimulant drug

Glenmark Pharmaceuticals Ltd has been granted final approval by the United States Food and Drug Administration (USFDA) for Amphetamine Sulfate tablets USP

Glenmark Pharma gets tentative nod from USFDA for blood thinning drug

Drug major Glenmark Pharma on Monday said it has received tentative approval from the US health regulator for anticoagulant Dabigatran Etexilate capsules

Pharma shares gain; Natco, Glenmark, Syngene, Sequent Scientific up over 5%

Patient footfalls are gaining traction in healthcare units as demand from non-Covid-19 patients is gathering pace, according to a November 25 report by CARE Ratings.

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug

Drug major Glenmark Pharma on Tuesday said it has received tentative approval from the US health regulator for Axitinib tablets, used in the treatment of kidney cancer. The tentatively approved product is the generic version of Inlyta tablets of PF Prism CV. Glenmark Pharmaceuticals Inc, USA has received tentative approval by the United States Food & Drug Administration (USFDA) for Axitinib tablets in the strength of 1 mg and 5 mg, the company said in a regulatory filing. Quoting IQVIA sales data for the 12 months ending October 2020, Glenmark Pharma said the Inlyta Tablets, 1 mg and 5 mg market achieved annual sales of approximately USD 518.8 million. Glenmark's current portfolio consists of 166 products authorised for distribution in the US market and 45 ANDA's pending approval with the USFDA.

Dr Reddy's to acquire select brands from Glenmark in Russia, Ukraine

Dr Reddy's Laboratories on Saturday said it had inked a pact with Glenmark Pharmaceuticals to acquire its select anti-allergy brands in Russia, Ukraine, Kazakhstan and Uzbekistan

As refinancing risks ease, S&P affirms Glenmark Pharma's 'BB-' rating

The rating agency has a stable outlook on Glenmark Pharma's rating and also removed it from 'CreditWatch'

Glenmark Pharmaceuticals gets US FDA approval for Tacrolimus Capsules USP

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg, the generic version of Prograf®1 Capsules, 0.5 mg, 1 mg and 5 mg, of Astellas Pharm US, Inc.According to IQVIATM sales data for the 12 month period ending September 2020, the Prograf® Capsules, 0.5 mg, 1 mg and 5 mg market2 achieved annual sales of approximately USD 286.8 million*.Glenmark's current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.1 All brand names and trademarks are the property of their respective owners.2 Market includes brand and all available therapeutic equivalents* IQVIATM National Sales .

Pharma shares underperform in a firm market; Glenmark, Ipca Labs fall 6%

In the past month, the S&P BSE Healthcare index underperformed the market by falling 5 per cent, as compared to 5.4 per cent rise in the S&P BSE Sensex

Glenmark Pharma launches pulmonary fibrosis treatment drug in India

Glenmark Pharma announced the launch of its generic version of Nintedanib (NINDANIB), used for the treatment of pulmonary fibrosis, in India

Smaller pharma firms post faster domestic sales growth in September

Barring Cipla and Glenmark, whose sales have grown in double digits due to demand for their Covid-19 drugs like favipiravir, tocilizumab, most big players have posted tepid growth

Glenmark's antiviral combination for moderate Covid-19 shows no benefit

The trial's findings confirm that the addition of umifenovir does not show any incremental benefit in clinical outcomes, the company said

No significant benefit of Umifenovir in Covid-19 treatment: Glenmark

Drug firm Glenmark Pharmaceuticals on Friday said the addition of antiviral Umifenovir did not demonstrate any significant clinical benefit over Favipiravir alone in moderate COVID-19 patients. The clinical study evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-19 infection," Monika Tandon Senior VP & Head, Clinical ...

Higher sales in domestic market, lower costs bode well for Glenmark

The other trigger for the stock is the cost savings from lower investments in R&D and fund raising for innovation research

Glenmark: Domestic sales performance, lower costs bode well for the stock

Funding for its innovation subsidiary is a key trigger

Covid-19 drug sales shine even as domestic pharma market slows down

Major therapy areas show decline or low single-digit growth

Glenmark Pharma leaps 7% after posting two-fold jump in Q1 profit

The company's other income for the quarter rose to Rs 58.5 crore from Rs 1.7 crore

Glenmark Q1 net jumps over two-fold, revenue up marginally at Rs 2,344.8 cr

"We focussed on controlling costs on all fronts and will continue with these efforts for the remaining part of the financial year," Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said